BELLUS Health Announces Pricing of US$200 Million Public Offering in Canada and the United States

Breadcrumb Trail Links

Author of the article:

Publishing date:

Dec 14, 2021  •  26 minutes in the past  •  4 minute learn  • 


Article content material

Common Shares Priced at US$8.00 per Share

LAVAL, Quebec — In reference to its beforehand introduced public providing of widespread shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU) right this moment introduced that it has entered into an underwriting settlement with a syndicate of underwriters comprising Jefferies, Evercore ISI and RBC Capital Markets as joint book-running managers, and together with LifeSci Capital as lead supervisor and H.C. Wainwright & Co. and Bloom Burton as co-managers (collectively, the “Underwriters”), regarding the public providing of 25,000,000 widespread shares. The shares are being bought at a public providing value of US$8.00 per widespread share. Closing of the Offering is predicted to happen on December 17, 2021, topic to the satisfaction of customary closing situations. In addition, the Underwriters have been granted a 30-day possibility following the date hereof to buy as much as an extra 3,750,000 widespread shares from the Company.

This commercial has not loaded but, however your article continues under.

Article content material

The Offering is being made in Canada pursuant to a prospectus complement (the “Supplement”) to the Company’s amended and restated quick kind base shelf prospectus dated December 14, 2021 (the “A&R Base Shelf Prospectus”) and in the United States pursuant to a registration assertion on Form F-10, as it might be amended every now and then, containing the Supplement and A&R Base Shelf Prospectus filed with the U.S. Securities and Exchange Commission (the “SEC”) in accordance with the Multijurisdictional Disclosure System established between Canada and the United States.


The Company intends to make use of the web proceeds of the Offering primarily to fund analysis and growth actions, common and administrative bills, working capital wants and different common company functions, as set out in the Supplement.

The Company’s widespread shares are listed on the Toronto Stock Exchange (the “TSX”) and the Nasdaq Global Market (“Nasdaq”) underneath the image “BLU”. For the functions of the TSX approval, the Company intends to depend on the exemption set forth in Section 602.1 of the TSX Company Manual, which gives that the TSX is not going to apply its requirements to sure transactions involving eligible interlisted issuers on a acknowledged change, comparable to Nasdaq.

The Supplement and the accompanying A&R Base Shelf Prospectus include essential detailed details about the Offering. The Supplement and the accompanying A&R Base Shelf Prospectus might be discovered on SEDAR at and on EDGAR at . Copies of the Supplement and accompanying A&R Base Shelf Prospectus can also be obtained from the Company, by phone at 450-680-4500 or by electronic mail at [email protected] or you might request them from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by phone at 877-821-7388 or by electronic mail at [email protected] ; or Evercore Group L.L.C., Attention: Equity Capital Markets , 55 East 52 nd Street, 35 th Floor, New York, NY 10055, by phone at 888-474-0200 or by electronic mail at [email protected] ; or RBC Capital Markets, LLC, Attention: Equity Capital Markets, 200 Vesey Street, eighth Floor, New York, New York 10281, by phone at (877) 822-4089 or by electronic mail at [email protected] . Prospective traders ought to learn the Supplement and accompanying A&R Base Shelf Prospectus and the different paperwork the Company has filed earlier than investing determination.

This commercial has not loaded but, however your article continues under.


Article content material

No regulatory authority has both accepted or disapproved the contents of this information launch. This information launch shall not represent a suggestion to promote or the solicitation of a suggestion to purchase, nor shall there be any sale of these securities in any province, state or jurisdiction in which such supply, solicitation or sale can be illegal previous to the registration or qualification underneath the securities legal guidelines of any such province, state or jurisdiction.

About BELLUS Health

BELLUS Health Inc. is a clinical-stage biopharmaceutical firm creating novel therapeutics for the remedy of refractory continual cough (“RCC”) and different hypersensitization-related issues. The Company’s product candidate, BLU-5937, is being developed for the remedy of adults with RCC.

Cautionary Note Regarding Forward-­‐Looking Statements

Certain statements contained in this information launch, aside from statements of reality which might be independently verifiable at the date hereof, might represent “forward-looking statements” inside the that means of Canadian securities laws and laws, the U.S. Private Securities Litigation Reform Act of 1995, as amended, and different relevant securities legal guidelines. Such statements, primarily based as they’re on the present expectations of administration, inherently contain quite a few essential dangers, uncertainties and assumptions, identified and unknown. In this information launch, such forward-looking statements embody, however will not be restricted to, statements relating to the Offering, the granting of the choice to buy extra shares and the anticipated use of proceeds from the Offering. Completion of the Offering is topic to quite a few elements, many of that are past BELLUS Heath’s management, together with however not restricted to, market situations, the failure of the events to fulfill sure closing situations and different essential elements disclosed beforehand and every now and then in BELLUS Health’s filings with the securities regulatory authorities in every of the provinces and territories of Canada and the SEC. Actual future occasions might differ from the anticipated occasions expressed in such forward-looking statements. BELLUS Health believes that expectations represented by forward-looking statements are cheap, but there might be no assurance that such expectations will show to be appropriate. The reader mustn’t place undue reliance, if any, on any forward-looking statements included in this information launch. These forward-looking statements communicate solely as of the date made, and BELLUS Health is underneath no obligation and disavows any intention to replace publicly or revise such statements consequently of any new data, future occasion, circumstances or in any other case, except required by relevant securities legal guidelines.

View supply model on



Ramzi Benamar
Chief Financial Officer
[email protected]

Julia Deutsch
Solebury Trout
[email protected]


Share this text in your social community

This commercial has not loaded but, however your article continues under.

By clicking on the join button you consent to obtain the above publication from Postmedia Network Inc. You might unsubscribe any time by clicking on the unsubscribe hyperlink at the backside of our emails. Postmedia Network Inc. | 365 Bloor Street East, Toronto, Ontario, M4W 3L4 | 416-383-2300


Postmedia is dedicated to sustaining a energetic however civil discussion board for dialogue and encourage all readers to share their views on our articles. Comments might take as much as an hour for moderation earlier than showing on the website. We ask you to maintain your feedback related and respectful. We have enabled electronic mail notifications—you’ll now obtain an electronic mail in case you obtain a reply to your remark, there may be an replace to a remark thread you observe or if a consumer you observe feedback. Visit our Community Guidelines for extra data and particulars on the right way to modify your email settings.

Show More

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button